Daily Sepsis Research Analysis
Three high-impact studies advance sepsis science across mechanisms, pathogens, and therapeutics. New work shows mitochondrial complex III-derived superoxide is essential for IL-10 secretion and protection from endotoxic shock. A conserved bacterial SDR family drives outer membrane vesicle–mediated virulence, while an oral, intestine-targeted macrophage-mimetic nanotherapy curbs intestinal injury and improves survival in septic mice.
Summary
Three high-impact studies advance sepsis science across mechanisms, pathogens, and therapeutics. New work shows mitochondrial complex III-derived superoxide is essential for IL-10 secretion and protection from endotoxic shock. A conserved bacterial SDR family drives outer membrane vesicle–mediated virulence, while an oral, intestine-targeted macrophage-mimetic nanotherapy curbs intestinal injury and improves survival in septic mice.
Research Themes
- Immunometabolism and mitochondrial signaling in sepsis
- Gram-negative virulence via outer membrane vesicles and host-pathogen interactions
- Targeted nanotherapies protecting the intestinal barrier in sepsis
Selected Articles
1. Mitochondria complex III-generated superoxide is essential for IL-10 secretion in macrophages.
Macrophage mitochondrial complex III-derived superoxide is required for IL-10 secretion after TLR3/4 stimulation. Complex III-deficient mice are more susceptible to endotoxic shock, and PKA activation rescues IL-10 release, implicating an immunometabolic axis central to sepsis tolerance.
Impact: Reveals a previously unappreciated requirement for mitochondrial ROS in anti-inflammatory cytokine release and shock protection, opening avenues to modulate cAMP/PKA signaling in sepsis.
Clinical Implications: Although preclinical, targeting mitochondrial signaling or cAMP/PKA pathways to restore IL-10 could augment host tolerance in sepsis or endotoxemia.
Key Findings
- Complex III-deficient macrophages secrete less IL-10 after TLR3/4 stimulation, and mice show increased susceptibility to IAV and LPS endotoxic shock.
- Restoring respiration with AOX without superoxide generation failed to rescue IL-10 release or shock susceptibility.
- PKA activation restored IL-10 secretion in complex III-deficient BMDMs; IL-4 responses were unaffected by complex III deficiency.
Methodological Strengths
- Genetically defined macrophage-specific complex III deficiency with in vivo infection and endotoxic shock models
- Mechanistic rescue experiments using AOX and PKA activation across multiple TLR stimuli
Limitations
- Mechanistic link between complex III superoxide and PKA signaling remains indirect
- Translational relevance to human sepsis not yet established; limited to murine and BMDM models
Future Directions: Define molecular intermediates linking complex III superoxide to cAMP/PKA and IL-10 transcription; test pharmacologic modulators in sepsis models and human macrophages.
Mitochondrial electron transport chain (ETC) function modulates macrophage biology; however, mechanisms underlying mitochondria ETC control of macrophage immune responses are not fully understood. Here, we report that mutant mice with mitochondria ETC complex III (CIII)-deficient macrophages exhibit increased susceptibility to influenza A virus (IAV) and LPS-induced endotoxic shock. Cultured bone marrow-derived macrophages (BMDMs) isolated from these mitochondria CIII-deficient mice released less IL-10 than controls following TLR3 or TLR4 stimulation. Unexpectedly, restoring mitochondrial respiration without generating superoxide using alternative oxidase (AOX) was not sufficient to reverse LPS-induced endotoxic shock susceptibility or restore IL-10 release. However, activation of protein kinase A (PKA) rescued IL-10 release in mitochondria CIII-deficient BMDMs following LPS stimulation. In addition, mitochondria CIII deficiency did not affect BMDM responses to interleukin-4 (IL-4) stimulation. Thus, our results highlight the essential role of mitochondria CIII-generated superoxide in the release of anti-inflammatory IL-10 in response to TLR stimulation.
2. Uncovering a new family of conserved virulence factors that promote the production of host-damaging outer membrane vesicles in gram-negative bacteria.
A conserved SDR family (CprA/HlyF orthologs) drives outer membrane vesicle production that blocks autophagy and enhances non-canonical inflammasome activation, increasing Gram-negative virulence. Deletion of cprA reduces virulence in a murine sepsis model, highlighting anti-virulence targets.
Impact: Defines a cross-species virulence mechanism linking SDR enzymes to OMV-mediated host damage, providing tractable anti-virulence targets relevant to sepsis.
Clinical Implications: Targeting SDR-driven OMV biogenesis or restoring autophagic flux may attenuate Gram-negative virulence without exerting antibiotic pressure.
Key Findings
- CprA expression induces OMVs that block autophagic flux and enhance non-canonical inflammasome activation.
- P. aeruginosa lacking cprA shows reduced virulence in a murine sepsis model.
- SDR orthologs in E. coli (HlyF), Y. pestis, and R. solanacearum similarly promote OMV production and autophagy blockade.
Methodological Strengths
- Integration of molecular genetics, cell biology of autophagy/inflammasome, and in vivo sepsis virulence testing
- Cross-species validation demonstrating conservation of the virulence mechanism
Limitations
- Quantitative contribution of OMV-mediated effects to overall virulence across diverse clinical isolates remains to be defined
- Translational relevance to human infection and therapeutic targeting needs in vivo pharmacologic validation
Future Directions: Develop small-molecule or biologic inhibitors of SDR-driven OMV biogenesis; test host-directed strategies to restore autophagy and blunt inflammasome activation in sepsis models.
CprA is a short-chain dehydrogenase/reductase (SDR) that contributes to resistance against colistin and antimicrobial peptides. The cprA gene is conserved across Pseudomonas aeruginosa clades and its expression is directly regulated by the two-component system PmrAB. We have shown that cprA expression leads to the production of outer membrane vesicles (OMVs) that block autophagic flux and have a greater capacity to activate the non-canonical inflammasome pathway. In a murine model of sepsis, a P. aeruginosa strain deleted for cprA was less virulent than the wild-type (WT) strain. These results demonstrate the important role of CprA in the pathogenicity of P. aeruginosa. It is worth noting that CprA is also a functional ortholog of hemolysin F (HlyF), which is encoded by virulence plasmids of Escherichia coli. We have shown that other cryptic SDRs encoded by mammalian and plant pathogens, such as Yersinia pestis and Ralstonia solanacearum are functional orthologs of CprA and HlyF. These SDRs also induce the production of OMVs which block autophagic flux. This study uncovers a new family of virulence determinants in Gram-negative bacteria, offering potential for innovative therapeutic interventions and deeper insights into bacterial pathogenesis.
3. Intestine-Decipher Engineered Capsules Protect Against Sepsis-induced Intestinal Injury via Broad-spectrum Anti-inflammation and Parthanatos Inhibition.
An oral, pH-responsive capsule delivering macrophage membrane-coated olaparib nanoparticles targets injured intestine in sepsis, neutralizes cytokines, inhibits PARP1-driven parthanatos, reduces bacterial translocation, and improves survival in mice.
Impact: Introduces a dual-function, host-directed oral nanotherapy that addresses intestinal barrier failure—a central driver of sepsis progression—with survival benefits in vivo.
Clinical Implications: If translatable, intestine-targeted, macrophage-mimetic nanoparticles could complement standard care by protecting the gut barrier and modulating hyperinflammation in sepsis.
Key Findings
- Macrophage membrane-coated olaparib nanoparticles (OLA@MΦ NPs) in pH-responsive capsules resist gastric acid and release in the intestine, targeting injured tissue.
- Released nanoparticles neutralize pro-inflammatory cytokines via macrophage membrane receptors and inhibit PARP1-mediated parthanatos in intestinal epithelium.
- In septic mice, the therapy reduces bacterial translocation, attenuates sepsis progression, and improves survival.
Methodological Strengths
- Rational nanomedicine design with biomimetic targeting and controlled intestinal release
- In vivo demonstration of survival benefit alongside mechanistic readouts (cytokines, parthanatos, bacterial translocation)
Limitations
- Preclinical murine study; human safety, dosing, and manufacturability remain untested
- Potential off-target immunomodulation and long-term effects of PARP inhibition in the gut are unknown
Future Directions: Evaluate pharmacokinetics, safety, and efficacy in large animals; optimize capsule release profiles; and investigate combinatorial regimens with standard sepsis care.
Sepsis is a severe systemic inflammatory syndrome characterized by a dysregulated immune response to infection, often leading to high mortality rates. The intestine, owing to its distinct structure and physiological environment, plays a pivotal role in the pathophysiology of sepsis. It functions as the "central organ" or "engine" in the progression of sepsis, with intestinal injury exacerbating the condition. Despite the availability of current therapies that offer partial symptom relief, they fall short of adequately protecting the intestinal barrier. In this study, an advanced nanodrug formulation (OLA@MΦ NPs) is developed by coating macrophage membranes onto polymeric organic nanoparticles encapsulating olaparib. When loaded into pH-responsive capsules, an intestine-decipher engineered capsule (cp-OLA@MΦ NPs) is successfully formulated. Upon oral administration in septic mice, these capsules withstand gastric acid and release their contents in the intestine, specifically targeting injured tissues. The released OLA@MΦ NPs effectively neutralize pro-inflammatory cytokines via macrophage membrane receptors, while olaparib inhibits intestinal epithelial parthanatos (a form of programmed cell death) by suppressing poly(ADP-ribose) polymerase 1 (PARP1) activation. This strategy significantly reduces bacterial translocation, slows the progression of sepsis, and enhances survival in septic mice, thus presenting a promising therapeutic approach for sepsis in clinical applications.